Onswik-Insulin Efsitora Alfa-Gobe
Onswik (insulin efsitora alfa) is a long-acting insulin therapy indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Administered as a once-weekly subcutaneous injection, Onswik is designed to provide basal insulin activity over an extended dosing interval. Like other insulin therapies, it helps lower blood […]
Isembyld-Apitegromab-Mstn
Isembyld (apitegromab) is a monoclonal antibody indicated for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are receiving an SMN2-targeted treatment. Unlike therapies that primarily address the underlying SMN protein deficiency, apitegromab is designed to target muscle loss by inhibiting the activation of myostatin, […]
NexoBrid-Anacaulase-Bcdb
Removing dead tissue from deep burns has traditionally required surgical excision, which sacrifices some viable tissue and carries blood loss and grafting consequences. NexoBrid (anacaulase) offered an enzymatic alternative. Its bromelain-derived proteolytic enzymes selectively dissolve burn eschar while largely sparing the viable tissue underneath, reducing the need for surgical debridement. The topical gel is applied […]
Briumvi-Ublituximab-Xiiy
B-cell depletion became a mainstay of multiple sclerosis treatment, where infusion time and dosing convenience increasingly drive product choice. Briumvi (ublituximab) competes primarily on those terms. Glycoengineered for enhanced antibody-dependent cytotoxicity, it achieves effective B-cell depletion at lower doses, allowing one-hour maintenance infusions twice a year. The intravenous anti-CD20 antibody treats relapsing forms of multiple […]
Lunsumio-Mosunetuzumab-Axgb
Follicular lymphoma relapses repeatedly, and each line of therapy narrows the options that remain. Lunsumio (mosunetuzumab) brought off-the-shelf T-cell engagement to that setting. It binds CD20 on lymphoma cells and CD3 on T cells, redirecting the immune system to destroy them. Given as a fixed-duration intravenous course with step-up dosing, it treats adults with relapsed […]
Tzield-Teplizumab-Mzwv
Tzield (teplizumab) became the first therapy to delay type 1 diabetes rather than manage it, in a disease that had only ever been treated by replacing insulin. This anti-CD3 monoclonal antibody modulates autoreactive T cells to help preserve remaining insulin-producing beta cell function. A 14-day course of daily intravenous infusions delays the onset of Stage […]
Elahere-Mirvetuximab Soravtansine-Gynx
Platinum-resistant ovarian cancer has poor outcomes and few targeted options, while folate receptor alpha is overexpressed in most cases. Elahere (mirvetuximab soravtansine) turned that into a treatment. It delivers the maytansinoid DM4 into tumor cells to disrupt microtubules, making it the first folate receptor alpha-directed antibody-drug conjugate approved. The intravenous therapy treats FR-alpha-positive, platinum-resistant epithelial […]
Tecvayli-Teclistamab-Cqyv
Tecvayli (teclistamab) delivered BCMA targeting as an off-the-shelf antibody, sidestepping the manufacturing time and specialized centers that CAR-T requires in late-line myeloma. Teclistamab binds BCMA on myeloma cells and CD3 on T cells, bridging them to trigger tumor cell killing as the first BCMA-directed bispecific antibody approved. Weekly subcutaneous injections follow step-up dosing in adults […]
Daxxify-Daxibotulinumtoixna-Lanm
The aesthetic neurotoxin market is mature and competitive, where differentiation comes from formulation and duration rather than mechanism. Daxxify (daxibotulinumtoxinA) entered on both counts. It temporarily blocks acetylcholine release at the neuromuscular junction, and unlike other formulations it uses a proprietary stabilizing peptide instead of human serum albumin. The injectable toxin treats moderate-to-severe glabellar lines […]
Spevigo-Spesolimab-Sbzo
Generalized pustular psoriasis flares are rare, painful, and potentially life-threatening, and treatment relied on agents borrowed off-label from plaque psoriasis. Spevigo (spesolimab) was the first therapy approved for the flares themselves. By blocking the IL-36 receptor, a pathway genetically implicated in the disease, it interrupts the cascade driving widespread pustule formation, with many patients clearing […]
